Donald Mitchell
Keine laufenden Positionen mehr
Profil
Donald Mitchell formerly worked at Idenix Pharmaceuticals LLC, as Executive Director-Corporate Development from 2005 to 2008, United States Navy (District of Columbia), as Communications Officer & Assistant Engineer, and F-Star Therapeutics, Inc. (United States), as Consultant from 2008 to 2011.
Mr. Mitchell received his undergraduate degree from United States Naval Academy and Masters Business Admin degree from the University of Virginia Darden School of Business.
Ehemalige bekannte Positionen von Donald Mitchell
| Unternehmen | Position | Ende |
|---|---|---|
| IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 01.01.2008 |
| United States Navy (District of Columbia) | Public Communications Contact | - |
| SPRING BANK PHARMACEUTICALS, INC. | Geschäftsführer | - |
Ausbildung von Donald Mitchell
| United States Naval Academy | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
F-Star Therapeutics, Inc. (United States)
 F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
| United States Navy (District of Columbia) | Government |
